{"nctId":"NCT00964795","briefTitle":"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)","startDateStruct":{"date":"2009-12"},"conditions":["Neovascular Age-related Macular Degeneration"],"count":323,"armGroups":[{"label":"Open-label Intravitreal Aflibercept Injection","type":"EXPERIMENTAL","interventionNames":["Drug: Intravitreal Aflibercept Injection 2mg"]}],"interventions":[{"name":"Intravitreal Aflibercept Injection 2mg","otherNames":["IAI; EYLEA®; BAY86-5321; VEGF Trap-Eye"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participation in Study VGFT-OD-0605 through week 96.\n* In the opinion of the investigator, the study eye has neovascular AMD and may continue to require treatment.\n\nExclusion Criteria:\n\n* Presence of any condition that would jeopardize the patient's participation in this study.\n* Females who are pregnant, breastfeeding, or of childbearing potential, unwilling to practice adequate contraception throughout the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Safety and Tolerability of Intravitreal Aflibercept Injection in Participants With Neovascular AMD","description":"The primary endpoint in the study is the safety and tolerability of Intravitreal Aflibercept Injection in patients with neovascular AMD (Age-related Macular Degeneration) from day 1 through the end of treatment visit (week 180) based on the number of participants who experienced any treatment-emergent adverse event (TEAE).\n\nTreatment-emergent adverse events were categorized according to Ocular TEAEs in the study eye, Ocular TEAEs in the fellow eye, and Non-Ocular TEAEs","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"290","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"232","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in BCVA Letter Score (mLOCF)","description":"The secondary endpoint in the study is the change in BCVA letter score from baseline through Week 116.\n\n(mLOCF: The last non-missing observation prior to the missing visit was carried forward to impute the missing data; no imputation after last visit; no baseline value carried forward).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"12.50"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Summary of Treatment Duration (Weeks)","description":"Treatment Duration = (last dose date - first dose date + 28)/7","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"110.4","spread":"42.16"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Summary of Study Duration (Weeks)","description":"Study Duration = (last visit/ discontinuation date - first dose date + 28)/7","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116.9","spread":"44.3"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":105,"n":323},"commonTop":["Retinal Haemorrhage","Retinal Haemorrhage","Age-Related Macular Degeneration","Conjunctival Haemorrhage","Hypertension"]}}}